Omalizumab use during pregnancy for CIU: a tertiary care experience.

Journal Article

The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.

Duke Authors

Cited Authors

  • Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C

Published Date

  • July 2016

Published In

Volume / Issue

  • 48 / 4

Start / End Page

  • 145 - 146

PubMed ID

  • 27425170

International Standard Serial Number (ISSN)

  • 1764-1489

Language

  • eng